本页面由Tiger Trade Technology Pte. Ltd.提供服务

Innate Pharma SA

1.48
-0.1400-8.64%
盘后:1.480.00000.00%16:00 EDT
成交量:3.35万
成交额:5.01万
市值:1.66亿
市盈率:-2.53
高:1.53
开:1.48
低:1.46
收:1.62
52周最高:2.71
52周最低:1.17
股本:1.12亿
流通股本:8,844.50万
量比:0.52
换手率:0.04%
股息:- -
股息率:- -
每股收益(TTM):-0.5840
每股收益(LYR):-0.6458
净资产收益率:-271.37%
总资产收益率:-46.60%
市净率:-3.67
市盈率(LYR):-2.29

数据加载中...

2020/04/14

非美公司披露报告

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/04/14

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/10

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/10

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/02/03

超过5%披露

Statement of acquisition of beneficial ownership by individuals
2020/01/14

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/01/09

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/01/02

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/12/13

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/12/09

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/12/06

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2019/10/25

超过5%披露

General statement of acquisition of beneficial ownership
2019/10/23

超过5%披露

Statement of acquisition of beneficial ownership by individuals
2019/10/17

[补充]招股说明书

Filing under Securities Act Rules 163/433 of free writing prospectuses
2019/10/17

[补充]招股说明书

Filing under Securities Act Rules 163/433 of free writing prospectuses
2019/10/11

SEC问询函

[Cover]Correspondence
2019/10/11

SEC问询函

[Cover]Correspondence
2019/10/04

[修订]招股说明书

[Amend] Registration statement for certain foreign private issuers
2019/09/20

招股说明书

Registration statement for certain foreign private issuers